Piramal Pharma Share Price Today: Piramal Pharma Limited (NSE: PPLPHARMA) is in the Big Live spotlight Today, April 29, 2026, following its audited Q4 FY26 results released yesterday. The Latest management commentary provides a Big bullish outlook for the new fiscal year. The company has officially guided for double-digit revenue growth in FY27, driven by a strong order book in the CDMO (Contract Development and Manufacturing) segment and a Live recovery in Complex Hospital Generics (CHG). Crucially, the Latest guidance suggests that EBITDA and PAT are expected to grow faster than revenue, signaling a Big focus on margin expansion and operational excellence.
Piramal Pharma Share Price Today: Why a 2.6% Dip on Results Day Is Hiding a Much Bigger FY27 Story
Quick Highlights: The Latest Big Financial Snapshot
- FY26 Consolidated Revenue: ₹8,869 Crore (Marginal decline due to H1 destocking).
- Latest Q4 Performance: Consolidated net loss of ₹8.82 Million (significantly reduced from Q3).
- Big FY27 Target: Double-digit revenue growth with accelerated Live profitability.
- Specialty Growth: India Consumer Healthcare (PCH) grew 17% in Q4, led by Power Brands.
- Stock Price Today: ₹164.30 (Down 2.64% in a Live sideways trend).
Key Market Data (Live: April 29, 2026)
| Metric | Latest Value | Big Performance Trend |
| Current Market Price (NSE) | ₹164.30 | Live Consolidation |
| Market Capitalization | ₹21,700+ Cr | Big Pharma Mid-cap |
| Net Debt (FY26) | ₹4,140 Cr | Latest Debt Reduction Focus |
| EBITDA Margin (Q4) | 18.4% | Live Operational Excellence |
| Analyst Rating | Sideways/Hold | Upgraded from Latest “Sell” |
Why It Happened: The Big Growth & Recovery Triggers
The Latest FY27 guidance is supported by three Big drivers dominating the Live market sentiment:
- CDMO Execution & Capacity: The Big news is the ramp-up of the Lexington and Riverview facilities in the US. With 209 customer audits completed in FY26 (the highest ever), the Latest data suggests a massive Live pipeline of complex molecules that will fuel the FY27 revenue surge.
- Complex Hospital Generics (CHG) Recovery: After facing execution hurdles, the Latest acquisition of Kenalog and leadership in Inhalation Anesthesia (47% market share) has positioned the segment for Big growth. Supplies from the Live lower-cost Digwal facility are expected to boost margins significantly in FY27.
- Consumer Healthcare Momentum: The Latest 24% growth in “Power Brands” (Lacto Calamine, Little’s) and a 48% jump in E-commerce sales provide a Big steady cash-flow cushion. Management expects this Live momentum to sustain with improved margins through premiumization.
Market Context & Technical Trends
The Live sentiment for Piramal Pharma has shifted from Latest “Mildly Bearish” to a “Sideways Trend” Today. While the stock saw a 2.6% dip on results day, the Big technical takeaway is the Live accumulation seen in the weekly MACD. Brokerages like ICICI Direct and Motilal Oswal maintain Latest target prices of ₹190–₹230, representing a Big 15–40% upside as the FY27 guidance begins to materialize.
Also read about Maruti Suzuki Q4 Results FY26
What It Means for Investors
The Latest board meeting confirmed that the Big “Execution Phase” has begun. The Big news for shareholders is the Live zero-increase in net debt over the last year, despite a Latest $94 Million capex. For those tracking the Live price, the Big resistance is at ₹182, while the Latest support floor is firmly at ₹155.
Frequently Asked Questions (FAQ)
1. What is Piramal Pharma’s guidance for FY27?
The company has guided for Latest double-digit revenue growth in FY27, with Big EBITDA and PAT expected to grow at a faster rate than the top line.
2. Why did Piramal Pharma report a loss in FY26?
The Latest consolidated loss of ₹326 Cr for FY26 was primarily due to a Big one-time impairment charge of ₹176 Cr and inventory destocking in the Live first half of the year.
3. What is the Big update on the CDMO business Today?
Piramal Pharma achieved its Latest “highest-ever” customer audits (209) in FY26, signaling a Big surge in technical interactions and order book visibility for FY27.
4. What is the Latest target price for Piramal Pharma?
Analysts at ICICI Direct have a Big target of ₹230, while the Live consensus target ranges between ₹190 and ₹211.
Conclusion
Today, Piramal Pharma has demonstrated Why it is the Big turnaround pick for the pharmaceutical sector. The Latest FY27 guidance and Live capacity expansions prove that the company is effectively navigating Big global headwinds. As the Latest financial year begins, Piramal Pharma remains a Big favorite for investors seeking Live exposure to high-margin contract manufacturing and specialty generics.
Disclaimer: The views expressed are for informational purposes only and do not constitute financial advice. Investing in stocks and IPOs involves significant risk.forgeup.in is not liable for any financial losses. Always consult a certified investment advisor before making any decisions.